Optimized GVHD Prevention in HLA-Mismatched Unrelated Allogeneic HCT Using a PTCY-Based Approach. (PubMed, Eur J Haematol) - Mar 5, 2025 - "Although post-transplant cyclophosphamide (PTCY)-based prophylaxis has become a widely adopted strategy for preventing graft-versus-host disease (GVHD) in 9 out of 10 HLA-mismatched unrelated donors (MMUDs), allogeneic hematopoietic cell transplants (allo-HCTs), data on the safety and efficacy of PTCY in this setting remain limited...By Day +30, 40.8% of patients experienced bacterial bloodstream infections, and 52.4% had cytomegalovirus (CMV) reactivation before letermovir prophylaxis...HLA Class I or II mismatches did not affect key outcomes or GVHD rates. These findings demonstrate that PTCY-Tac offers effective GVHD prevention and favorable outcomes in MMUD allo-HCT, supporting its application for patients without fully matched donors."
Journal • Acute Graft versus Host Disease • Chronic Graft versus Host Disease • Cytomegalovirus Infection • Graft versus Host Disease • Hematological Disorders • Hematological Malignancies • Immunology • Infectious Disease • Oncology • Transplantation
|
|
Alexandra Pedraza; Carles Serra; Carmen Martinez; Cristina Moreno; Enric Carreras; Filipe R Pinto; Francesc Fernández-Avilés; Gerard Corrius; Joan Cid; Jordi Esteve; Laia Guardia; Laura Rosiñol; Maria Queralt Salas; Maria Suárez-Lledó; Miquel Lozano; Montserrat Rovira; Noemí de Llobet; Paola Charry
|